Abstract Scope In January 2021, the ESCMID Executive Committee decided to launch a new
initiative to develop ESCMID guidelines on several COVID-19-related issues, including
treatment of COVID-19. Methods An ESCMID COVID-19 guidelines task force was
established by the ESCMID Executive Committee. A small group was established, half
appointed by the chair, and the remaining selected with an open call. Each panel met
virtually once a week. For all decisions, a simple majority vote was used. A long list of …

In their living guidelines for the treatment of hospitalized patients with coronavirus disease
2019 (COVID-19), Bartoletti and colleagues make a conditional recommendation to use
remdesivir (RDV) in patients not on mechanical ventilation (MV) or extracorporeal
membrane oxygenation (ECMO)[1]. The benefit of RDV has been shown only in the ACTT-1
placebo-controlled randomized clinical trial which showed a faster time to recovery.
However, the uptake of corticosteroids in the ACCTT-1 trial was low, and corticosteroids …